Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market was valued at USD 1.0 Billion in 2022 and is projected to reach USD 1.6 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030.
The Vascular Endothelial Growth Factor (VEGF) inhibitors market in Japan has been a focal point in the pharmaceutical industry, particularly concerning treatments for various ocular diseases. However, recent data indicates a significant shift in this landscape.
Market Overview
In 2024, Japan's anti-VEGF therapeutics market generated revenue of approximately USD 204.8 million. Projections suggest a decline to USD 121.2 million by 2030, reflecting a Compound Annual Growth Rate (CAGR) of -8.9% from 2025 to 2030. This downturn contrasts with the global trend, where the demand for such therapeutics remains robust.
Key Products and Market Segments
Eylea (Aflibercept): In 2024, Eylea emerged as the largest revenue-generating product in Japan's anti-VEGF market. Its efficacy in treating conditions like age-related macular degeneration (AMD) and diabetic retinopathy has solidified its position among healthcare professionals.
Beovu (Brolucizumab): Despite the overall market contraction, Beovu is anticipated to be the most lucrative product segment, registering the fastest growth during the forecast period. Its introduction offers an alternative for patients unresponsive to existing treatments.
Industry Requirements and Strategic Initiatives
The pharmaceutical industry's focus has been on innovation and addressing unmet medical needs. Companies are actively engaging in strategic initiatives to introduce novel treatments and expand their product portfolios:
Novartis AG: In May 2020, Novartis introduced Beovu in Japan for AMD treatment. This launch underscores the company's commitment to offering innovative solutions in the ophthalmology sector.
DAIICHI SANKYO COMPANY, LIMITED: The company launched a biosimilar of Avastin (Bevacizumab) in December 2019. Although primarily used for oncology indications, its off-label use for AMD provides clinicians with more therapeutic options.
Factors Influencing Market Dynamics
Several elements contribute to the projected decline in Japan's anti-VEGF market:
Demographic Shifts: Japan's aging population has led to a higher prevalence of ocular diseases. However, improved early detection and preventive measures have reduced the progression to stages requiring anti-VEGF therapies.
Healthcare Policies: Government initiatives promoting cost-effective treatments and the adoption of biosimilars have impacted the sales of branded anti-VEGF drugs.
Technological Advancements: Emerging therapies, such as gene therapy and sustained-release drug delivery systems, offer potential alternatives to traditional anti-VEGF injections, influencing market dynamics.
Global Context and Future Outlook
While Japan's anti-VEGF market faces challenges, the global landscape tells a different story. For instance, the 100 Gigabit Fiber Optic Transceiver Market is experiencing rapid growth, driven by the expansion of data centers and the increasing demand for high-speed data transmission. This contrast highlights the varying dynamics across different sectors and regions.
In conclusion, the Japan VEGF inhibitors market is undergoing a transformative phase. Industry stakeholders must adapt to the evolving landscape by focusing on innovation, strategic collaborations, and aligning with healthcare policies to meet the changing demands effectively.
Get an In-Depth Research Analysis of the Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size And Forecast [2025-2032]
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc
Sanofi.
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market
Monoclonal Antibodies
Small Molecule Inhibitors
Fusion Proteins
Gene Therapy Products
Oncology
Ophthalmology
Intravenous (IV)
Subcutaneous (SC)
Oral
Intraocular
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
Age Group
Gender
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Research Analysis
1. Introduction of the Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market, By Type
6. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market, By Application
7. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/